About: covid:PMC7448791

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7448791 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Alcaro, Stefano Alkhatib, Mohammad Ambrosio, Francesca Artese, Anna Assaraf, Yehuda Ceccherini-Silberstein, Francesca Costa, Giosuè Salpini, Romina Santoro, Maria Svicher, Valentina Di Maio, Velia
is schema:about of	named entity 'coronaviruses' named entity 'druggable' named entity 'antiviral' named entity 'ritonavir' named entity 'asymptomatic' named entity 'remdesivir' named entity 'ExoN' named entity 'zanamivir' named entity 'infection' named entity 'amino acid residues' named entity 'molecular recognition' named entity 'conserved domain' named entity 'RNA' named entity 'drug resistance' named entity 'SARS-CoV-2' named entity 'binding affinity' named entity 'hydrogen bonds' named entity 'antiviral activity' named entity 'prodrug' named entity 'remdesivir' named entity 'N-linked glycosylation' named entity 'hydrogen bonding' named entity 'sputum' named entity 'serum' named entity 'catalytic site' named entity 'ExoN' named entity 'clinical practice' named entity 'RdRp' named entity 'drug resistance' named entity 'antiviral' named entity 'region 1' named entity 'nucleotide analogue' named entity 'catalytic domain' named entity 'ExoN' named entity 'Griffithsin' named entity 'antiviral' named entity 'ribavirin' named entity 'RNA viruses' named entity 'MERS-CoV' named entity 'supplemental oxygen' named entity 'proline' named entity 'lead optimization' named entity 'glycoprotein' named entity 'severe acute respiratory syndrome coronavirus' named entity 'ventilator' named entity 'ribavirin' named entity '100 %' named entity 'ACE2' named entity 'Bavari' named entity 'highly conserved' named entity 'Ebola' named entity 'HIV' named entity 'RdRp' named entity 'pharmacological' named entity 'PDB' named entity 'larotrectinib' named entity 'coronavirus' named entity 'cell culture' named entity 'SARS-CoV-2' named entity 'RdRp' named entity 'infection' named entity 'RdRp' named entity 'salt bridge' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'remdesivir' named entity 'uracil' named entity 'remdesivir' named entity 'chymotrypsin' named entity 'malaria' named entity 'Chloroquine' named entity 'ribavirin' named entity 'lipopeptide' named entity 'genetic conservation' named entity 'SARS-CoV-2' named entity 'ACE2 receptor' named entity 'viral load' named entity 'cation' named entity 'HCoV-229E' named entity 'viral replication' named entity 'conserved regions' named entity 'medical community' named entity 'randomized clinical trial' named entity 'antibacterial' named entity 'amino acid' named entity 'HR2' named entity 'treatment regimens' named entity 'DrugBank' named entity 'antivirals'

Attributes

Values

Creator

Alcaro, Stefano
Alkhatib, Mohammad
Ambrosio, Francesca
Artese, Anna
Assaraf, Yehuda
Ceccherini-Silberstein, Francesca
Costa, Giosuè
Salpini, Romina
Santoro, Maria
Svicher, Valentina
Di Maio, Velia

is schema:about of

named entity 'coronaviruses'
named entity 'druggable'
named entity 'antiviral'
named entity 'ritonavir'
named entity 'asymptomatic'
named entity 'remdesivir'
named entity 'ExoN'
named entity 'zanamivir'
named entity 'infection'
named entity 'amino acid residues'
named entity 'molecular recognition'
named entity 'conserved domain'
named entity 'RNA'
named entity 'drug resistance'
named entity 'SARS-CoV-2'
named entity 'binding affinity'
named entity 'hydrogen bonds'
named entity 'antiviral activity'
named entity 'prodrug'
named entity 'remdesivir'
named entity 'N-linked glycosylation'
named entity 'hydrogen bonding'
named entity 'sputum'
named entity 'serum'
named entity 'catalytic site'
named entity 'ExoN'
named entity 'clinical practice'
named entity 'RdRp'
named entity 'drug resistance'
named entity 'antiviral'
named entity 'region 1'
named entity 'nucleotide analogue'
named entity 'catalytic domain'
named entity 'ExoN'
named entity 'Griffithsin'
named entity 'antiviral'
named entity 'ribavirin'
named entity 'RNA viruses'
named entity 'MERS-CoV'
named entity 'supplemental oxygen'
named entity 'proline'
named entity 'lead optimization'
named entity 'glycoprotein'
named entity 'severe acute respiratory syndrome coronavirus'
named entity 'ventilator'
named entity 'ribavirin'
named entity '100 %'
named entity 'ACE2'
named entity 'Bavari'
named entity 'highly conserved'
named entity 'Ebola'
named entity 'HIV'
named entity 'RdRp'
named entity 'pharmacological'
named entity 'PDB'
named entity 'larotrectinib'
named entity 'coronavirus'
named entity 'cell culture'
named entity 'SARS-CoV-2'
named entity 'RdRp'
named entity 'infection'
named entity 'RdRp'
named entity 'salt bridge'
named entity 'SARS-CoV-2'
named entity 'COVID'
named entity 'remdesivir'
named entity 'uracil'
named entity 'remdesivir'
named entity 'chymotrypsin'
named entity 'malaria'
named entity 'Chloroquine'
named entity 'ribavirin'
named entity 'lipopeptide'
named entity 'genetic conservation'
named entity 'SARS-CoV-2'
named entity 'ACE2 receptor'
named entity 'viral load'
named entity 'cation'
named entity 'HCoV-229E'
named entity 'viral replication'
named entity 'conserved regions'
named entity 'medical community'
named entity 'randomized clinical trial'
named entity 'antibacterial'
named entity 'amino acid'
named entity 'HR2'
named entity 'treatment regimens'
named entity 'DrugBank'
named entity 'antivirals'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software